BR0110547A - Anticorpo purificado, métodos para induzir seletivamente morte celular em células alvo e para tratar um indivìduo com cancer e que tem uma doença inflamatória ou doença autoimune, processos para inibir proliferação de células alvo, para tratar um indivìduo com uma doença relacionada a apoptose, para produzir um anticorpo humanizado e para aumentar nìveis de nfkb em uma célula, composição, uso de um anticorpo , ácido nucleico isolado, vetor, célula cultivada, polipeptìdio purificado, e, kit comercial para induzir apoptose - Google Patents
Anticorpo purificado, métodos para induzir seletivamente morte celular em células alvo e para tratar um indivìduo com cancer e que tem uma doença inflamatória ou doença autoimune, processos para inibir proliferação de células alvo, para tratar um indivìduo com uma doença relacionada a apoptose, para produzir um anticorpo humanizado e para aumentar nìveis de nfkb em uma célula, composição, uso de um anticorpo , ácido nucleico isolado, vetor, célula cultivada, polipeptìdio purificado, e, kit comercial para induzir apoptoseInfo
- Publication number
- BR0110547A BR0110547A BR0110547-7A BR0110547A BR0110547A BR 0110547 A BR0110547 A BR 0110547A BR 0110547 A BR0110547 A BR 0110547A BR 0110547 A BR0110547 A BR 0110547A
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- antibody
- methods
- treating
- individual
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 230000001939 inductive effect Effects 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 239000013598 vector Substances 0.000 title abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 208000034615 apoptosis-related disease Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000030833 cell death Effects 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 title 2
- 230000006907 apoptotic process Effects 0.000 title 1
- 230000004663 cell proliferation Effects 0.000 title 1
- 210000004748 cultured cell Anatomy 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 abstract 1
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 102000053594 human TNFRSF10B Human genes 0.000 abstract 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 abstract 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20134400P | 2000-05-02 | 2000-05-02 | |
| PCT/US2001/014151 WO2001083560A1 (en) | 2000-05-02 | 2001-05-02 | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0110547A true BR0110547A (pt) | 2004-06-22 |
Family
ID=22745456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0110547-7A BR0110547A (pt) | 2000-05-02 | 2001-05-02 | Anticorpo purificado, métodos para induzir seletivamente morte celular em células alvo e para tratar um indivìduo com cancer e que tem uma doença inflamatória ou doença autoimune, processos para inibir proliferação de células alvo, para tratar um indivìduo com uma doença relacionada a apoptose, para produzir um anticorpo humanizado e para aumentar nìveis de nfkb em uma célula, composição, uso de um anticorpo , ácido nucleico isolado, vetor, célula cultivada, polipeptìdio purificado, e, kit comercial para induzir apoptose |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US7244429B2 (enExample) |
| EP (4) | EP1287035B1 (enExample) |
| JP (4) | JP4156238B2 (enExample) |
| KR (2) | KR20060092292A (enExample) |
| CN (2) | CN100497388C (enExample) |
| AT (1) | ATE426615T1 (enExample) |
| AU (2) | AU2001259366B2 (enExample) |
| BG (3) | BG65929B1 (enExample) |
| BR (1) | BR0110547A (enExample) |
| CA (1) | CA2407965C (enExample) |
| CY (1) | CY1109179T1 (enExample) |
| CZ (2) | CZ304614B6 (enExample) |
| DE (1) | DE60138097D1 (enExample) |
| DK (1) | DK1287035T3 (enExample) |
| EE (1) | EE05548B1 (enExample) |
| ES (1) | ES2323448T3 (enExample) |
| HU (2) | HU229417B1 (enExample) |
| IL (1) | IL152605A0 (enExample) |
| MX (1) | MXPA02010823A (enExample) |
| NO (2) | NO329843B1 (enExample) |
| NZ (1) | NZ522881A (enExample) |
| PL (1) | PL211733B1 (enExample) |
| PT (1) | PT1287035E (enExample) |
| RU (1) | RU2298013C2 (enExample) |
| TW (1) | TWI318983B (enExample) |
| WO (1) | WO2001083560A1 (enExample) |
| ZA (1) | ZA200209230B (enExample) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7528239B1 (en) | 1997-02-13 | 2009-05-05 | Immunex Corporation | Receptor that binds trail |
| NZ337795A (en) | 1997-03-17 | 2001-06-29 | Human Genome Sciences Inc | Death domain containing receptor 5 and it's use in the treatment of DR5 related disease |
| US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| WO2000066156A1 (en) * | 1999-05-04 | 2000-11-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| US7476383B2 (en) | 2000-05-02 | 2009-01-13 | The Uab Research Foundation | Antibody selective for DR4 and uses thereof |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| US20060062786A1 (en) * | 2000-11-08 | 2006-03-23 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US20030228309A1 (en) * | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
| AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US8071740B2 (en) * | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| JP3665316B2 (ja) * | 2001-05-18 | 2005-06-29 | 麒麟麦酒株式会社 | 抗ｔｒａｉｌ−ｒ抗体 |
| DK1572874T3 (da) | 2001-05-25 | 2013-12-16 | Human Genome Sciences Inc | Antistoffer, der immunospecifikt binder til TRAIL receptorer |
| US7361341B2 (en) * | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| US20050214209A1 (en) * | 2001-05-25 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
| US20090226429A1 (en) * | 2001-05-25 | 2009-09-10 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
| US20050129616A1 (en) * | 2001-05-25 | 2005-06-16 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| CA2463816C (en) | 2001-10-19 | 2014-07-08 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| ES2357225T3 (es) * | 2001-11-01 | 2011-04-20 | Uab Research Foundation | Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos. |
| NZ533164A (en) * | 2001-11-01 | 2008-09-26 | Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| AU2002361784A1 (en) * | 2001-12-20 | 2003-07-09 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| EP2075256A2 (en) | 2002-01-14 | 2009-07-01 | William Herman | Multispecific binding molecules |
| DE10210427A1 (de) * | 2002-03-09 | 2003-10-09 | Hans Konrad Mueller-Hermelink | Humaner monoklonaler Antikörper |
| CA2491669A1 (en) | 2002-07-04 | 2004-01-15 | Oncomab Gmbh | Neoplasm specific antibodies and uses thereof |
| AU2008201431B2 (en) * | 2002-11-27 | 2011-11-24 | Irm, Llc | Methods and compositions for inducing Apoptosis in cancer cells |
| DE60334247D1 (de) * | 2002-11-27 | 2010-10-28 | Irm Llc | Verfahren und zusammensetzungen zur apoptoseinduktion in krebszellen |
| DE10311248A1 (de) | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper |
| DE10353175A1 (de) | 2003-11-14 | 2005-06-16 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper mit fettsenkender Wirkung |
| EP1531162A1 (en) | 2003-11-14 | 2005-05-18 | Heinz Vollmers | Adenocarcinoma specific antibody SAM-6, and uses thereof |
| EP1756162A1 (en) * | 2004-03-23 | 2007-02-28 | Biogen Idec MA Inc. | Receptor coupling agents and therapeutic uses thereof |
| CN100427505C (zh) * | 2004-08-19 | 2008-10-22 | 中国医学科学院基础医学研究所 | 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体（ad5-10）及其制法与用途 |
| CN101065401B (zh) * | 2004-12-13 | 2012-10-24 | 赛弗隆澳大利亚(Vic)私人有限公司 | 骨保护素变异蛋白 |
| EP1846034A4 (en) | 2005-02-02 | 2010-11-10 | Uab Research Foundation | AGENTS AND METHODS OF REDUCING THE RESISTANCE TO APOPTOSIS INDUCING DEATH RECEPTOR AGONISTS |
| US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
| JP5004154B2 (ja) * | 2005-04-06 | 2012-08-22 | 一般財団法人化学及血清療法研究所 | 組換え抗ボツリヌス神経毒素抗体 |
| CA2611519A1 (en) | 2005-06-17 | 2006-12-28 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
| CN101300273B (zh) * | 2005-08-31 | 2013-05-22 | 安姆根有限公司 | Trail受体2多肽和抗体 |
| PE20071101A1 (es) * | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| US8232377B2 (en) | 2006-05-16 | 2012-07-31 | National Institute Of Advanced Industrial Science And Technology | Method for high-level secretory production of protein |
| WO2008094176A2 (en) * | 2006-06-19 | 2008-08-07 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
| KR100847010B1 (ko) * | 2006-07-05 | 2008-07-17 | 아주대학교산학협력단 | 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물 |
| KR100804126B1 (ko) | 2007-02-09 | 2008-02-19 | 아주대학교산학협력단 | 종양 괴사 인자―관련 세포사멸―유도 리간드의 수용체에특이적으로 결합하는 1가의 인간 단일클론 항체 및 그의항원결합 단편 |
| WO2008154439A1 (en) * | 2007-06-08 | 2008-12-18 | Irm Llc | Methods and compositions for inducing apoptosis in cancer cells |
| EP2177230A4 (en) * | 2007-08-09 | 2011-04-27 | Daiichi Sankyo Co Ltd | IMMUNOLIPOSOM AS INDUCTOR OF APOPTOSIS INTO DEATH DOMAIN-CONTAINING RECEPTOR EXPRESSING CELL |
| EP2210940B2 (en) | 2007-10-31 | 2018-07-18 | Daiichi Sankyo Company, Limited | Method for high-level secretion and production of protein |
| WO2010047509A2 (ko) * | 2008-10-24 | 2010-04-29 | 아주대학교 산학협력단 | 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물 |
| CA2775350A1 (en) * | 2009-09-24 | 2011-03-31 | Seattle Genetics, Inc. | Dr5 ligand drug conjugates |
| KR101278690B1 (ko) * | 2009-10-19 | 2013-06-24 | 한올바이오파마주식회사 | 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법 |
| KR20120101050A (ko) | 2009-11-05 | 2012-09-12 | 더 유에이비 리서치 파운데이션 | 기저형 유전자형 암의 치료 방법 |
| WO2011084623A1 (en) | 2009-12-16 | 2011-07-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment |
| US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| NZ602368A (en) | 2010-02-12 | 2014-10-31 | Pharmascience Inc | Iap bir domain binding compounds |
| US8703712B2 (en) | 2010-03-18 | 2014-04-22 | The Uab Research Foundation | Targeting cancer stem cells with DR5 agonists |
| CN103282495B (zh) | 2010-10-29 | 2017-06-09 | 第一三共株式会社 | 新的抗dr5抗体 |
| CA2830349C (en) | 2011-03-17 | 2019-07-16 | The University Of Birmingham | Re-directed immunotherapy |
| MX2013012716A (es) * | 2011-05-03 | 2014-03-21 | Genentech Inc | Agentes de disociacion vascular y sus usos. |
| WO2014012165A1 (en) | 2012-07-19 | 2014-01-23 | Alethia Biotherapeutics Inc. | Anti-siglec-15 antibodies |
| SG11201500489YA (en) * | 2012-07-25 | 2015-02-27 | Kolltan Pharmaceuticals Inc | Anti-kit antibodies and uses thereof |
| CN103074425B (zh) * | 2012-12-29 | 2014-01-01 | 深圳市第三人民医院 | Cd263基因的用途 |
| US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| CN104710533A (zh) * | 2013-12-12 | 2015-06-17 | 中国科学院深圳先进技术研究院 | sDR5-Fc融合蛋白及其用途 |
| US10689449B2 (en) | 2015-01-20 | 2020-06-23 | Igm Biosciences, Inc. | Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof |
| AU2015380455A1 (en) | 2015-01-26 | 2017-08-03 | Macrogenics, Inc. | Multivalent molecules comprising DR5-binding domains |
| CN105061604B (zh) * | 2015-08-19 | 2018-03-16 | 河南大学 | sDR5‑Fc融合蛋白突变体及其应用 |
| WO2017075484A2 (en) | 2015-10-30 | 2017-05-04 | Galaxy Biotech, Llc | Highly potent antibodies binding to death receptor 4 and death receptor 5 |
| MX2018006333A (es) | 2015-12-01 | 2018-08-01 | Genmab Bv | Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos. |
| CN106924735A (zh) * | 2015-12-29 | 2017-07-07 | 上海交通大学医学院附属瑞金医院 | 多巴胺1类受体激动剂在制备肿瘤治疗药物中的用途 |
| US10849912B2 (en) | 2016-02-09 | 2020-12-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment |
| MX2018010445A (es) | 2016-03-01 | 2019-10-17 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Anticuerpos especificos del receptor de poliovirus humano (rvp). |
| KR101926166B1 (ko) * | 2016-05-24 | 2018-12-06 | 재단법인 아산사회복지재단 | 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법 |
| US11680101B2 (en) | 2017-01-27 | 2023-06-20 | Kymab Limited | Anti-OPG antibodies |
| KR101926834B1 (ko) | 2017-03-21 | 2018-12-07 | 동아에스티 주식회사 | 항-dr5 항체 및 그의 용도 |
| CN111328335A (zh) | 2017-06-07 | 2020-06-23 | 根马布私人有限公司 | 基于突变igg六聚体的治疗性抗体 |
| KR101951025B1 (ko) | 2017-08-17 | 2019-02-21 | 서울대학교산학협력단 | 세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물 |
| TWI826393B (zh) * | 2017-09-22 | 2023-12-21 | 美商免疫遺傳股份有限公司 | 使用陽離子交換層析法分離三輕鏈抗體 |
| WO2019100193A1 (zh) * | 2017-11-21 | 2019-05-31 | 深圳先进技术研究院 | 抗dr5的抗体及其制备方法和应用 |
| WO2019100194A1 (zh) * | 2017-11-21 | 2019-05-31 | 深圳先进技术研究院 | 抗dr5的抗体及其制备方法和应用 |
| CN108251443A (zh) * | 2018-01-23 | 2018-07-06 | 深圳市人民医院 | 一种tnfrsf10c重组质粒、制备方法及其应用 |
| WO2019173499A1 (en) | 2018-03-06 | 2019-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 17-beta-hydroxywithanolides and use thereof in treating cancer |
| CN117003874A (zh) | 2018-03-20 | 2023-11-07 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| AU2019402097A1 (en) | 2018-12-17 | 2021-06-10 | Revitope Limited | Twin immune cell engager |
| EP4277706A1 (en) | 2021-01-15 | 2023-11-22 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9028123D0 (en) * | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
| US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| US6433147B1 (en) | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
| ATE362982T1 (de) | 1997-01-28 | 2007-06-15 | Human Genome Sciences Inc | ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET |
| US6072047A (en) | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
| US6313269B1 (en) | 1997-03-14 | 2001-11-06 | Smithkline Beecham Corporation | Tumor necrosis factor related receptor, TR6 |
| NZ337795A (en) | 1997-03-17 | 2001-06-29 | Human Genome Sciences Inc | Death domain containing receptor 5 and it's use in the treatment of DR5 related disease |
| US6872568B1 (en) * | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| AU734758B2 (en) | 1997-04-01 | 2001-06-21 | Sankyo Company Limited | Anti-fas antibodies |
| CA2287085A1 (en) | 1997-04-16 | 1998-10-22 | Millennium Biotherapeutics, Inc. | Tumor necrosis factor receptor related proteins tango-63d and tango-63e |
| US6342369B1 (en) * | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
| ES2293682T5 (es) | 1997-05-15 | 2011-11-17 | Genentech, Inc. | Anticuerpo anti-apo2. |
| WO1999002653A1 (en) | 1997-07-11 | 1999-01-21 | Trustees Of The University Of Pennsylvania | Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use |
| JP2001510042A (ja) * | 1997-07-15 | 2001-07-31 | イミュネックス・コーポレーション | Ｔｒａｉｌ受容体 |
| WO1999007861A1 (en) | 1997-08-06 | 1999-02-18 | Laboratório Medinfar-Produtos Farmacêuticos, Lda. | DNA INTEGRATION INTO 'MYCOBACTERIUM spp.' GENOME BY TRANS-COMPLEMENTATION USING A SITE-SPECIFIC INTEGRATION SYSTEM |
| AU8861898A (en) * | 1997-08-13 | 1999-03-08 | Ufe Solar Gmbh | Sorption trap arrangement and method for storing heat |
| WO1999009165A1 (en) | 1997-08-15 | 1999-02-25 | Idun Pharmaceuticals, Inc. | Trail receptors, nucleic acids encoding the same, and methods of use thereof |
| AU9376498A (en) | 1997-09-05 | 1999-03-22 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
| JP4357738B2 (ja) | 1997-09-12 | 2009-11-04 | アポテック エール エ デ− エス．アー． | システインリッチなレセプターであるｔｒａｉｎ |
| US7105640B2 (en) * | 1997-10-17 | 2006-09-12 | Genentech, Inc. | Anti-pro792 antibodies |
| US20040120947A1 (en) | 1998-01-26 | 2004-06-24 | Genentech, Inc. | DR4 antibodies and uses thereof |
| IL137176A0 (en) | 1998-01-26 | 2001-07-24 | Genentech Inc | Antibodies to 4dr and uses thereof |
| US6252050B1 (en) | 1998-06-12 | 2001-06-26 | Genentech, Inc. | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method |
| US6534061B1 (en) | 1999-04-12 | 2003-03-18 | Genentech, Inc. | Tumor necrosis factor receptor homologs and nucleic acids encoding the same |
| WO2000066156A1 (en) | 1999-05-04 | 2000-11-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| AU4984300A (en) | 1999-05-06 | 2000-11-21 | Vishva M Dixit | Death domain containing receptor 4 |
| DK1181319T3 (da) | 1999-05-28 | 2009-08-17 | Genentech Inc | Kimære DR4-antistoffer og anvendelser deraf |
| PT1192185E (pt) | 1999-06-09 | 2006-11-30 | Genentech Inc | Sinergismo de agonista do receptor de apo-2l e cpt-11 |
| US6294546B1 (en) | 1999-08-30 | 2001-09-25 | The Broad Of Trustees Of The Leland Stanford Junior University | Uses of diterpenoid triepoxides as an anti-proliferative agent |
| EP1226161A2 (en) | 1999-09-15 | 2002-07-31 | Genentech, Inc. | Apo-2 receptor antibodies |
| DK1272647T3 (en) | 2000-04-11 | 2014-12-15 | Genentech Inc | Multivalent antibodies and uses thereof |
| US7476383B2 (en) * | 2000-05-02 | 2009-01-13 | The Uab Research Foundation | Antibody selective for DR4 and uses thereof |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| US20030228309A1 (en) * | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
| CA2426710A1 (en) | 2000-11-08 | 2002-10-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| US6965023B2 (en) * | 2000-11-17 | 2005-11-15 | The Burnham Institute | Death domain proteins |
| EP1409544B1 (en) | 2001-07-03 | 2009-06-17 | Genentech, Inc. | Human dr4 antibodies and uses thereof |
| NZ533164A (en) | 2001-11-01 | 2008-09-26 | Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| ES2357225T3 (es) | 2001-11-01 | 2011-04-20 | Uab Research Foundation | Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos. |
-
2001
- 2001-05-01 TW TW090110398A patent/TWI318983B/zh not_active IP Right Cessation
- 2001-05-02 EP EP01932876A patent/EP1287035B1/en not_active Expired - Lifetime
- 2001-05-02 US US10/275,180 patent/US7244429B2/en not_active Expired - Lifetime
- 2001-05-02 NZ NZ522881A patent/NZ522881A/en not_active IP Right Cessation
- 2001-05-02 AT AT01932876T patent/ATE426615T1/de active
- 2001-05-02 HU HU0400951A patent/HU229417B1/hu not_active IP Right Cessation
- 2001-05-02 DE DE60138097T patent/DE60138097D1/de not_active Expired - Lifetime
- 2001-05-02 ES ES01932876T patent/ES2323448T3/es not_active Expired - Lifetime
- 2001-05-02 KR KR1020067015043A patent/KR20060092292A/ko not_active Ceased
- 2001-05-02 AU AU2001259366A patent/AU2001259366B2/en not_active Expired
- 2001-05-02 JP JP2001580185A patent/JP4156238B2/ja not_active Expired - Lifetime
- 2001-05-02 DK DK01932876T patent/DK1287035T3/da active
- 2001-05-02 RU RU2002132255/13A patent/RU2298013C2/ru active
- 2001-05-02 CA CA2407965A patent/CA2407965C/en not_active Expired - Lifetime
- 2001-05-02 EP EP08021292.1A patent/EP2065401B1/en not_active Expired - Lifetime
- 2001-05-02 BR BR0110547-7A patent/BR0110547A/pt not_active Application Discontinuation
- 2001-05-02 AU AU5936601A patent/AU5936601A/xx active Pending
- 2001-05-02 WO PCT/US2001/014151 patent/WO2001083560A1/en not_active Ceased
- 2001-05-02 PT PT01932876T patent/PT1287035E/pt unknown
- 2001-05-02 CN CNB018120385A patent/CN100497388C/zh not_active Expired - Lifetime
- 2001-05-02 CN CN200910137028.9A patent/CN101585881B/zh not_active Expired - Lifetime
- 2001-05-02 IL IL15260501A patent/IL152605A0/xx active IP Right Grant
- 2001-05-02 HU HU0500800A patent/HU230399B1/hu unknown
- 2001-05-02 EP EP10011253.1A patent/EP2368910B1/en not_active Expired - Lifetime
- 2001-05-02 CZ CZ2002-3917A patent/CZ304614B6/cs not_active IP Right Cessation
- 2001-05-02 KR KR1020027014707A patent/KR100817967B1/ko not_active Expired - Lifetime
- 2001-05-02 EP EP08021291.3A patent/EP2065400B1/en not_active Expired - Lifetime
- 2001-05-02 CZ CZ2006-291A patent/CZ306996B6/cs not_active IP Right Cessation
- 2001-05-02 EE EEP200200621A patent/EE05548B1/xx unknown
- 2001-05-02 MX MXPA02010823A patent/MXPA02010823A/es active IP Right Grant
- 2001-05-02 PL PL366195A patent/PL211733B1/pl not_active IP Right Cessation
-
2002
- 2002-11-01 NO NO20025253A patent/NO329843B1/no not_active IP Right Cessation
- 2002-11-13 ZA ZA200209230A patent/ZA200209230B/en unknown
- 2002-11-14 BG BG107275A patent/BG65929B1/bg unknown
- 2002-11-14 BG BG109275A patent/BG109275A/en unknown
-
2005
- 2005-04-11 JP JP2005113535A patent/JP3892466B2/ja not_active Expired - Lifetime
- 2005-08-23 BG BG109275A patent/BG66153B1/bg unknown
- 2005-09-06 NO NO20054145A patent/NO338228B1/no not_active IP Right Cessation
-
2006
- 2006-11-22 JP JP2006315093A patent/JP2007091749A/ja active Pending
-
2007
- 2007-06-08 US US11/760,491 patent/US7790165B2/en not_active Expired - Fee Related
-
2008
- 2008-07-29 JP JP2008194948A patent/JP4575975B2/ja not_active Expired - Lifetime
-
2009
- 2009-06-24 CY CY20091100656T patent/CY1109179T1/el unknown
-
2010
- 2010-06-24 US US12/822,732 patent/US8067001B2/en not_active Expired - Fee Related
-
2011
- 2011-10-10 US US13/269,811 patent/US8329180B2/en not_active Expired - Fee Related
-
2012
- 2012-09-17 US US13/621,383 patent/US8715668B2/en not_active Expired - Fee Related
-
2014
- 2014-03-12 US US14/206,797 patent/US9700618B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0110547A (pt) | Anticorpo purificado, métodos para induzir seletivamente morte celular em células alvo e para tratar um indivìduo com cancer e que tem uma doença inflamatória ou doença autoimune, processos para inibir proliferação de células alvo, para tratar um indivìduo com uma doença relacionada a apoptose, para produzir um anticorpo humanizado e para aumentar nìveis de nfkb em uma célula, composição, uso de um anticorpo , ácido nucleico isolado, vetor, célula cultivada, polipeptìdio purificado, e, kit comercial para induzir apoptose | |
| BR0213844A (pt) | anticorpo purificado que se liga especificamente a um receptor dr-4 do trail, anticorpo monoclonal, composição e kit para induzir seletivamente a apoptose em células alvo que expressam dr-4, para inibir a proliferação de células alvo que expressam dr-4, para tratar um paciente com cáncer, e um paciente tendo uma doença inflamatória ou auto-imune, ácido nucleico isolado, vetor, célula cultivada, e, polipeptìdeo purificado | |
| Bottino et al. | Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule | |
| Fiorenza et al. | Complex expression of murine heat shock transcription factors | |
| Lazaris-Karatzas et al. | Ras mediates translation initiation factor 4E-induced malignant transformation. | |
| Ben-Kasus et al. | Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis | |
| AU687897B2 (en) | Immunoreactive peptide sequence from a 43 KD human cancer antigen | |
| CN101310770A (zh) | 抗癌抗体 | |
| SG165161A1 (en) | Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof | |
| ES2274542T3 (es) | Anticuerpos frente al receptor del interferon alfa/beta. | |
| BR0213846A (pt) | métodos de induzir seletivamente a apoptose nas células alvo que expressam dr5, de inibir a proliferação de células alvo que expressam dr5 e de tratar um paciente tendo uma doença inflamatória ou doença autoimune, e, composição | |
| AU2002240719A1 (en) | Antibodies against cancer | |
| CN113874075A (zh) | 调节γC-细胞因子信号传导对于治疗脱发和脱发相关病症的影响 | |
| RU2550262C1 (ru) | Моноклональное антитело против интерлейкина-6 человека и гибридома, продуцирующая данное моноклональное антитело | |
| KR101783907B1 (ko) | ＣＤ66ｃ에 대한 항체와 화학치료제를 포함하는 폐암 예방 또는 치료용 약학조성물 | |
| Bernhard et al. | Recognition of Human Renal Cell Carcinoma and Melanoma by HLA‐A2‐Restricted Cytotoxic T Lymphocytes is Mediated by Shared Peptide Epitopes and Up‐Regulated by Interferon‐γ | |
| Park et al. | Induction of proline-rich tyrosine kinase2 (Pyk2) through C/EBPβ is involved in PMA-induced monocyte differentiation | |
| Bast et al. | Characterization of the colony-forming cell in monoclonal gammopathies | |
| Rème et al. | Growth and immortalization of human myeloma cells in immunodeficient severe combined immunodeficiency mice: a preclinical model | |
| Kawamoto et al. | Impaired tumor phenotypes in class II major histocompatibility complex antigen-inducible cells originated from human lung adenocarcinoma | |
| EP4491634A1 (en) | Anti-trop2 antibodies for use in treating immunosuppressed subjects | |
| Sun et al. | Antitumour activity of a chimeric antibody against the leucocyte antigen CD48 | |
| KR100808925B1 (ko) | 돼지 ｌａｇ-3 융합 이뮤노글로블린 | |
| Takayama et al. | Phenotypic change of an SV40‐transformed mouse macrophage line, BB‐W‐531–2, induced by different cultural methods | |
| Yoshida et al. | Induction of 19S IgM secretion in a murine pre-B cell line, 70Z/3, by cell hybridization with non-secreting myeloma cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] |
Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI |
|
| B10A | Cessation: cessation confirmed |
Free format text: HOMOLOGADA A DESISTENCIA DO PEDIDO SOLICITADA PELO DEPOSITANTE ATRAVES DA PETICAO NO 870160058101 DE 07/10/2016. |